Skip to search formSkip to main contentSkip to account menu

ganirelix

Known as: D-Alaninamide, N-acetyl-3-(1-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-N6-(bis(ethylamino)methylene)-L-lysyl-L-prolyl-, ganirelix [Chemical/Ingredient], GnRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)- 
National Institutes of Health

Related topics

Related topics

9 relations
Drug AllergyGanirelix acetateOvarian Hyperstimulation SyndromePregnancy

Broader (2)

GonadorelinHormone Antagonists

Narrower (2)

RS 26306orgalutran

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa.
2010
2010
Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation.
BACKGROUND A concern for new compounds in fertility treatment is the possible risk of perinatal complications or birth defects… 
2006
2006
Aging attenuates both the regularity and joint synchrony of LH and testosterone secretion in normal men: analyses via a model of graded GnRH receptor blockade.
Testosterone (T) secretion declines in the aging male, albeit for unknown reasons. From an ensemble perspective, repeated… 
2005
2005
Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment.
BACKGROUND This randomized controlled trial was designed to evaluate whether a GnRH antagonist given every other day could… 
Highly Cited
2004
Highly Cited
2004
Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF.
BACKGROUND The significance of suppressed LH levels in GnRH antagonist cycles for IVF outcome is currently unknown. The purpose… 
Highly Cited
2002
Highly Cited
2002
Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist.
Review
2002
Review
2002
Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix.
BACKGROUND To establish long-term safety, follow-up data on pregnancy, birth and neonatal outcome were collected during clinical… 
Review
2002
Review
2002
Safety aspects of gonadotrophin-releasing hormone antagonists in ovarian stimulation procedures: ovarian hyperstimulation syndrome and health of children born.
2001
2001
Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells.
OBJECTIVE GnRH antagonists have recently been introduced for the prevention of premature LH surges during controlled ovarian… 
2000
2000
Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor.
Recent suggestions that gonadotrophin-releasing hormone (GnRH) antagonists activate the GnRH receptor are discussed. Most of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)